There was an encouraging trend toward higher rates of early-stage diagnosis in 2023 (T1 17.5%, T2 42.3%, and T1/T2 59.8%) compared to 2021 (T1 14.1%, T2 39.7%, and T1/T2 53.8%).
← all excerpts
Rates and Factors Associated With Hepatocellular Carcinoma Diagnosis, Stage, Treatment, and Survival.
1
—
—